Determination of apovincaminic acid in human plasma by high-performance liquid chromatography using solid-phase extraction and ultraviolet detection

Cai, Jia; Tao, Weixing; N, Mei; Cao, Shilei; Jiang, Xinguo

doi:10.1016/j.jchromb.2005.10.052

Cited by 10 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GC methods based on prior derivatization had been used for the determination of AVA in biological samples [28,29]. While determination of AVA by HPLC with ultraviolet detection [30][31][32][33] and LC-MS [34] was more common. However, all these methods suffered from various drawbacks namely sensitivity, long chromatographic run times, large sample volume for processing or a cumbersome extraction procedure, which prevented their use for routine biological sample analysis.…”

Section: Vinpocetinementioning

confidence: 99%

Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography–tandem mass spectrometry

Xia

Guo

et al. 2010

Journal of Chromatography B

Self Cite

View full text Add to dashboard Cite

Section: Vinpocetinementioning

confidence: 99%

Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography–tandem mass spectrometry

Xia

Guo

et al. 2010

Journal of Chromatography B

Self Cite

View full text Add to dashboard Cite

“…In humans, vinpocetine is rapidly absorbed orally and subject to an intense first pass metabolic turnover during which the larger part of the substance is hydrolyzed into its active metabolite, cis‐ apovincaminic acid (cAVA) [9–11]. Therefore, the question came up whether this main metabolite plays an active role in the neuroprotective action of vinpocetine.…”

mentioning

confidence: 99%

Neuroprotective Effects of Vinpocetine and its Major Metabolite Cis‐apovincaminic Acid on NMDA‐Induced Neurotoxicity in a Rat Entorhinal Cortex Lesion Model

Nyakas

Felszeghy

Szabo

et al. 2009

CNS Neuroscience & Therapeutics

View full text Add to dashboard Cite

Vinpocetine (ethyl-apovincaminate, Cavinton), a synthetic derivative of the Vinca minor alkaloid vincamine, has been used now for decades for prevention and treatment of cerebrovascular diseases predisposing to development of dementia. Both vinpocetine and its main metabolite cis-apovincaminic acid (cAVA) exert a neuroprotective type of action. Bilateral N-methyl-D-aspartate (NMDA)-induced neurodegeneration in the entorhinal cortex of rat was used as a dementia model to confirm the neuroprotective action of these compounds in vivo. NMDA-lesioned rats were treated 60 min before lesion and throughout 3 postoperative days with a 10 mg/kg intraperitoneal dose of vinpocetine or cAVA. Behavioral tests started after termination of drug treatment and consisted of novel object recognition, social discrimination, and spontaneous alternation in a Y-maze, and spatial learning in the Morris water maze. At the end of behavioral testing brains were perfused with fixative and the size of the excitotoxic neuronal lesion and that of microglial activation around the lesion were assayed quantitatively on brain sections immunostained for neuron-specific nuclear protein (NeuN) and integrin CD11b, respectively. Entorhinal NMDA lesions impaired recognition of novel objects and the new social partner, and suppressed spontaneous alternation and spatial learning performance in the Morris maze. Both vinpocetine and cAVA effectively attenuated the behavioral deficits, and significantly decreased lesion size and the region of microglia activation. Both lesion-induced attention deficit and learning disabilities were markedly alleviated by vinpocetine and cAVA. The morphological findings corroborated the behavioral observations and indicated reduced lesion size and microglia activation especially after vinpocetine treatment which supports an in vivo neuroprotective mode of action of vinpocitine and a less potent action of cAVA.

show abstract

“…Several methods, such as GC [6], GC-MS [7,8], LC [9][10][11], LC-MS [5], and others [12] have been developed for separate determination of VP or AVA in plasma. To date, few studies on the simultaneous determination of VP and AVA in plasma by LS-MS-MS have been published [13,14].…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Estimation of Vinpocetine and Its Metabolite, Apovincaminic Acid, in Beagle Plasma by LC-MS-MS

Yang

Lou

Gong³

et al. 2011

Chromatographia

View full text Add to dashboard Cite

A method was developed to determine vinpocetine and its metabolite, apovincaminic acid, in beagle plasma by LC-MS-MS. After protein precipitation with methanol, the supernatant of the sample was concentrated and injected into an Agilent Zorbax XDB-C 18 column. The sample was separated by a mobile phase consisting of acetonitrile and 0.2% formic acid solution, and the reading was determined on an Agilent 6410 Triple Quad Tandem mass spectrometer in multiple reaction monitoring mode with the following transitions: m/z 351.5 ? 280.2/266.3 for vinpocetine, 323.2 ? 236.1/280.2 for apovincaminic acid, and 411.2 ? 191.1 for the internal standard. The intra-and inter-day variances were less than 15% (RSD%), and average recoveries were higher than 80%. The linearity ranges (LR) between 0.1 and 20.0 ng mL -1 for vinpocetine (r 2 = 0.9980) and between 1.0 and 200.0 ng mL -1 for apovincaminic acid (r 2 = 0.9995) were established. In summary, this method is sensitive, specific, and appropriate for in vivo study of various dosage forms of vinpocetine.

show abstract

Determination of apovincaminic acid in human plasma by high-performance liquid chromatography using solid-phase extraction and ultraviolet detection

Cited by 10 publications

References 9 publications

Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography–tandem mass spectrometry

Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography–tandem mass spectrometry

Neuroprotective Effects of Vinpocetine and its Major Metabolite Cis‐apovincaminic Acid on NMDA‐Induced Neurotoxicity in a Rat Entorhinal Cortex Lesion Model

Simultaneous Estimation of Vinpocetine and Its Metabolite, Apovincaminic Acid, in Beagle Plasma by LC-MS-MS

Contact Info

Product

Resources

About